Abraxis Bioscience, Inc. (1409012) SEC Filing 10-Q Quarterly report for the period ending Wednesday, June 30, 2010

Abraxis Bioscience, Inc.

CIK: 1409012

Exhibit 99.1

11755 Wilshire Blvd., 20th Floor

Los Angeles, CA 90025


News Release





ABRAXANE® First Quarter 2010 Revenue Grows 25% to $88 Million Compared to the First Quarter of 2009



Company Reports First Quarter 2010 Net Loss for Common Shareholders of $3 Million, or $0.07 Per Share, with Adjusted Net Income of $9 Million, or $0.22 Per Share

LOS ANGELES, Calif. May 6, 2010 — Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

First Quarter 2010 Highlights

Net revenue for the first quarter of 2010 was $110.8 million compared with $72.6 million for the first quarter of 2009. ABRAXANE® revenue for the first quarter of 2010 increased to $87.9 million compared with $70.1 million for the first quarter of 2009. Other product revenue and other revenue for the first quarter of 2010 increased to $22.9 million from $2.5 million in the first quarter of last year, primarily due to increased sales of raw material products and sales from Drug Source Company, LLC, an entity in which we obtained a controlling interest during the first quarter of 2010 and whose results of operations are now required to be consolidated into our financial statements.

Gross profit for the first quarter of 2010 was $88.2 million, or 80 percent of net revenue, compared with $63.5 million, or 87 percent of net revenue, for the first quarter of 2009. While gross profit increased due to higher sales volumes in the United States as well as increased net selling prices globally, the decrease in gross margin as a percentage of net revenue was caused primarily by an increase in sales of lower margin raw material products.


The following information was filed by Abraxis Bioscience, Inc. on Thursday, May 6, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Abraxis Bioscience, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abraxis Bioscience, Inc..


Assess how Abraxis Bioscience, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abraxis Bioscience, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2010 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1409012
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-10-179509
Submitted to the SEC: Thu Aug 05 2010 4:55:53 PM EST
Accepted by the SEC: Thu Aug 05 2010
Period: Wednesday, June 30, 2010
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink: